TY - JOUR
T1 - Multilevel challenges to equitable inclusion of children in trials when parents use languages other than English
T2 - A qualitative report from Children's Oncology Group's Diversity and Health Disparities Committee Language Equity Working Group
AU - Santacroce, Sheila Judge
AU - Beauchemin, Melissa P.
AU - Pelletier, Wendy
AU - Robles, Joanna M.
AU - Ruiz, Jenny
AU - Blazin, Lindsay J.
AU - Aristizabal, Paula
AU - Orjuela-Grimm, Manuela
AU - Hall, Anurekha G.
AU - Kahn, Justine
AU - Kline, Cassie
AU - Seif, Alix E.
AU - Velez, Maria C.
AU - Winestone, Lena E.
N1 - Publisher Copyright:
© 2024 Wiley Periodicals LLC.
PY - 2024
Y1 - 2024
N2 - Background: Increasing representation in clinical trials is a priority for the National Cancer Institute and Children's Oncology Group (COG). Our survey of COG-affiliated institutions revealed that many sites have insufficient processes and resources to enroll children whose parents use languages other than English (LOE). We describe reported barriers and facilitators to enrolling children in clinical trials when parents use LOE and propose opportunities for improvement. Procedures: We sent a 20-item survey to COG-affiliated institutions. Five items allowed respondents to expand on replies to questions about (a) local institutional review board (IRB) requirements regarding translation of consent documents, (b) contributors to provider discomfort consenting parents who use LOE, (c) available language services and resources, and (d) barriers to enrolling children whose parents use LOE or offer ideas about approaches to improvements. Two pairs of researchers independently coded free-text responses and compared results for concordance. Results: A total of 139 (N = 230; 60%) institutions returned the survey. Respondents were mainly physician principal investigators (n = 79/139; 57%) at the United States sites (n = 118/139; 85%) serving less than 100 newly diagnosed children per year (n = 99/139, 71%). They described challenges at multiple levels. Proposed approaches to improvements included centralized provision of translated materials and video educational materials in various languages, and collaborating with IRBs on regulatory processes that protect families and facilitate equitable clinical trial access. Conclusions: Clinical trial consortia, such as COG, face challenges in enrolling representative samples. Further research is required to design and implement multilevel interventions to ensure equitable access for all, regardless of language used, and mitigate disparate research participation.
AB - Background: Increasing representation in clinical trials is a priority for the National Cancer Institute and Children's Oncology Group (COG). Our survey of COG-affiliated institutions revealed that many sites have insufficient processes and resources to enroll children whose parents use languages other than English (LOE). We describe reported barriers and facilitators to enrolling children in clinical trials when parents use LOE and propose opportunities for improvement. Procedures: We sent a 20-item survey to COG-affiliated institutions. Five items allowed respondents to expand on replies to questions about (a) local institutional review board (IRB) requirements regarding translation of consent documents, (b) contributors to provider discomfort consenting parents who use LOE, (c) available language services and resources, and (d) barriers to enrolling children whose parents use LOE or offer ideas about approaches to improvements. Two pairs of researchers independently coded free-text responses and compared results for concordance. Results: A total of 139 (N = 230; 60%) institutions returned the survey. Respondents were mainly physician principal investigators (n = 79/139; 57%) at the United States sites (n = 118/139; 85%) serving less than 100 newly diagnosed children per year (n = 99/139, 71%). They described challenges at multiple levels. Proposed approaches to improvements included centralized provision of translated materials and video educational materials in various languages, and collaborating with IRBs on regulatory processes that protect families and facilitate equitable clinical trial access. Conclusions: Clinical trial consortia, such as COG, face challenges in enrolling representative samples. Further research is required to design and implement multilevel interventions to ensure equitable access for all, regardless of language used, and mitigate disparate research participation.
UR - http://www.scopus.com/inward/record.url?scp=85203131597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85203131597&partnerID=8YFLogxK
U2 - 10.1002/pbc.31321
DO - 10.1002/pbc.31321
M3 - Article
C2 - 39238140
AN - SCOPUS:85203131597
SN - 1545-5009
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
ER -